These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22004163)

  • 1. Lower eyelid melanoma during bimatoprost (Lumigan) therapy.
    Sun LL; Welch RT; Vu P
    Clin Exp Ophthalmol; 2012 Mar; 40(2):213-4. PubMed ID: 22004163
    [No Abstract]   [Full Text] [Related]  

  • 2. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy.
    Yam JC; Yuen NS; Chan CW
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):471-2. PubMed ID: 19857110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical bimatoprost 0.03% and iatrogenic eyelid and orbital lipodystrophy.
    Sira M; Verity DH; Malhotra R
    Aesthet Surg J; 2012 Sep; 32(7):822-4. PubMed ID: 22942109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of bimatoprost monotherapy in primary chronic angle closure and primary open angle glaucoma eyes: a three-year study.
    Gupta V; Srinivasan G; Sharma A; Kapoor KS; Sihota R
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):351-8. PubMed ID: 17803433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy.
    Sharpe ED; Reynolds AC; Skuta GL; Jenkins JN; Stewart WC
    Curr Eye Res; 2007 Dec; 32(12):1037-43. PubMed ID: 18085467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral upper eyelid retraction caused by topical bimatoprost therapy.
    Noma K; Kakizaki H
    Ophthalmic Plast Reconstr Surg; 2012; 28(2):e33-5. PubMed ID: 21562439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension.
    Katsanos A; Dastiridou AI; Fanariotis M; Kotoula M; Tsironi EE
    J Ocul Pharmacol Ther; 2011 Feb; 27(1):67-71. PubMed ID: 21214361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost.
    Sonty S; Donthamsetti V; Vangipuram G; Ahmad A
    J Ocul Pharmacol Ther; 2008 Oct; 24(5):517-20. PubMed ID: 18800869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periorbital changes associated with topical bimatoprost.
    Filippopoulos T; Paula JS; Torun N; Hatton MP; Pasquale LR; Grosskreutz CL
    Ophthalmic Plast Reconstr Surg; 2008; 24(4):302-7. PubMed ID: 18645437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma.
    Konstas AG; Holló G; Mikropoulos D; Tsironi S; Haidich AB; Embeslidis T; Georgiadou I; Irkec M; Melamed S
    Br J Ophthalmol; 2010 Feb; 94(2):209-13. PubMed ID: 19825835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Periocular cutaneous pigmentary changes associated with bimatoprost use.
    Galloway GD; Eke T; Broadway DC
    Arch Ophthalmol; 2005 Nov; 123(11):1609-10. PubMed ID: 16286629
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
    Ozturk F; Ermis SS; Inan UU
    Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of intraocular pressure-lowering effect of every night versus every other night dosing of bimatoprost 0.03%.
    Shazly TA; Latina MA
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):369-71. PubMed ID: 21663517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ocular surface side effects of topical travoprost and bimatoprost.
    Alagöz G; Bayer A; Boran C; Serin D; Kükner A; Elçioğlu M
    Ophthalmologica; 2008; 222(3):161-7. PubMed ID: 18497524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal adverse effects of prostaglandin analogues.
    Papachristou GC; Ritch R; Liebmann JM
    Arch Ophthalmol; 2008 May; 126(5):732-3. PubMed ID: 18474790
    [No Abstract]   [Full Text] [Related]  

  • 17. Hypertrichosis of the eyelashes caused by bimatoprost.
    Tosti A; Pazzaglia M; Voudouris S; Tosti G
    J Am Acad Dermatol; 2004 Nov; 51(5 Suppl):S149-50. PubMed ID: 15577756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iris heterochromia and unilateral eyelash hypertrichosis.
    Rao RC; Ballard TN; Chen TC
    JAMA; 2015 May; 313(19):1967-8. PubMed ID: 25988467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, prospective study of bimatoprost 0.01% or travoprost/timolol in patients previously treated with latanoprost and timolol to reduce intraocular pressure.
    Nixon DR
    J Ocul Pharmacol Ther; 2013 Dec; 29(10):876-81. PubMed ID: 24070367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study.
    Macky TA
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):605-10. PubMed ID: 21034177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.